Posted by Michael Wonder on 20 Apr 2023
Tezepelumab for the treatment of patients with severe asthma
20 April 2023 - NICE has published evidence based recommendations on tezepelumab (Tezspire) for the treatment of patients 12 years of age and older with severe asthma.
Tezepelumab as an add-on maintenance treatment is recommended as an option for severe asthma in people 12 years and over, when treatment with high-dose inhaled corticosteroids plus another maintenance treatment has not worked well enough. It is recommended only if people have had 3 or more exacerbations in the previous year, or are having maintenance oral corticosteroids.
Tezepelumab is recommended only if AstraZeneca provides it according to the commercial arrangement.
